TREATMENT OF DYSLIPIDEMIAS
 
Generic Brand Company Formulation Indications1

 

Slow
coronary
athero-
sclerosis		  Lower 
total-C		 Lower
LDL-C		 Increase
HDL-C		 Lower
apo B		 Lower
TG		 Sitosterol/
campesterol		 Reduce
risk of
CVD5
BILE ACID SEQUESTRANTS
Colesevelam Welchol Daiichi Sankyo tabs, oral susp

√




Cholestyramine resin Questran and Questran Light Par pwd
√


√
√
Colestipol Colestid Pfizer tabs, granules
√ √




CHOLESTEROL ABSORPTION INHIBITOR
Ezetimibe Zetia Merck tabs
√ √
√
√3
FIBRATES
Fenofibrate Antara Oscient caps
√ √ √ √ √

Lipofen Kowa caps
√ √ √ √ √

Lofibra Gate tabs, caps
√ √ √ √ √

Tricor Abbott tabs
√ √ √ √ √

Fenofibric acid Fibricor URL Pharma tabs
√ √ √ √ √

Trilipix Abbott caps (del-rel)
√ √ √ √ √

Gemfibrozil Lopid Pfizer tabs (scored) √2



√
√
LIPID-REGULATING AGENT
Omega-3-acid ethyl esters Lovaza GSK caps




√

NICOTINIC ACID DERIVATIVES
Niacin Niaspan Abbott tabs (ext-rel) √ √ √ √ √ √
√
STATINS (HMG-COA REDUCTASE INHIBITORS)
Atorvastatin Lipitor Pfizer tabs
√ √ √ √ √
√
Fluvastatin Lescol Novartis caps √ √ √ √ √ √
√
Lescol XL Novartis tabs (ext-rel) √ √ √ √ √ √
√
Lovastatin Mevacor Merck tabs √ √ √ √ √

√
Altoprev Sciele Pharma tabs (ext-rel) √ √ √ √ √ √
√
Pitavastatin Livalo Kowa and Lilly tabs
√ √ √ √ √

Pravastatin Pravachol Bristol-Myers Squibb tabs √ √ √ √ √ √
√
Rosuvastatin Crestor AstraZeneca tabs √ √ √4 √ √ √
√
Simvastatin Zocor Merck tabs
√ √ √ √ √
√
COMBINATION STATIN & CALCIUM CHANNEL BLOCKER
Atorvastatin + Amlodipine Caduet Pfizer tabs
√ √ √ √ √
√
COMBINATION STATIN & CHOLESTEROL ABSORPTION INHIBITOR
Simvastatin + Ezetimibe Vytorin Merck tabs
√ √ √ √ √

COMBINATION STATIN & NIACIN
Lovastatin + Niacin Advicor Abbott tabs (immediate + ext-rel)
√ √ √ √ √
Simvastatin + Niacin Simcor Abbott tabs (immediate + ext-rel)
√ √ √ √ √

NOTES

1 FDA-approved for indications (abbreviated here) marked with a √. Not a complete list of official indications. For a more complete description of indications, see indi-vidual product entries and/or contact company for full labeling. Indications listed may be adjunctive to other therapies, including lifestyle changes (eg, diet) and concomitant drugs.

2 Reduction in risk of coronary artery disease when first line agent is inadequate

3 To reduce elevated sitosterol and campes-terol in homozygous familial sitosterolemia

4 Also to reduce elevated non-HDL-C (total-C minus HDL-C)

5 To reduce risk of: MI, stroke, or coronary revascularization procedures, and morbidity/mortality.

For more information see the drug entries in this section or contact the company marketing the product.

Classification of Hyperlipoproteinemias
 Fredrickson Type Elevated Lipoproteins Lipid Elevations (Major) Lipid Elevations (Minor)
 I (rare) chylomicrons triglycerides total-C elevated or no change
 IIa LDL total-C —
 IIb LDL, VLDL total-C triglycerides
 III (rare) IDL total-C/triglycerides —
 IV VLDL triglycerides total-C elevated or no change
 V chylomicrons, VLDL triglycerides total-C elevated or no change
ABBREVIATIONS:

apo B = apolipoprotein B;  TG = triglycerides;  total-C = total cholesterol;  LDL-C = low-density lipoproteins; CVD = cardiovascular disease; IDL = intermediate-density lipoproteins;  VLDL = very low density lipoproteins;  HDL-C = high-density lipoproteins

(Rev. 8/2010)